Omega Therapeutics, Inc. announced new preclinical data supporting the potential of OTX-2101, a c-MYC-targeting epigenomic controller (MYC-EC) being developed for the treatment of non-small cell lung cancer (NSCLC), in combination with immune checkpoint inhibitors or EGFR inhibitors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which took place in Boston, Mass., October 11 -- 15, 2023. These new data build on previous results demonstrating anti-tumor activity of OTX-2101 as a monotherapy in preclinical NSCLC models and highlight its potential ability to synergize with clinically validated strategies. These encouraging results give confidence in OTX-2101's potential as meaningful new treatment option for patients living with NSCLC.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.115 USD | -0.70% | -3.42% | -29.73% |
May. 06 | Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 16 | Omega Therapeutics CFO Joshua Reed to Depart | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.73% | 117M | |
+52.93% | 63.85B | |
-2.53% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.22% | 26.52B | |
-21.41% | 18.69B | |
+2.62% | 12.73B | |
+22.42% | 12.11B | |
+27.60% | 12.07B |
- Stock Market
- Equities
- OMGA Stock
- News Omega Therapeutics, Inc.
- Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC